US20050222615A1 - Hemostasis pad and method - Google Patents
Hemostasis pad and method Download PDFInfo
- Publication number
- US20050222615A1 US20050222615A1 US11/125,765 US12576505A US2005222615A1 US 20050222615 A1 US20050222615 A1 US 20050222615A1 US 12576505 A US12576505 A US 12576505A US 2005222615 A1 US2005222615 A1 US 2005222615A1
- Authority
- US
- United States
- Prior art keywords
- glucosamine
- poly
- pad
- biopolymer
- tubular element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000023597 hemostasis Effects 0.000 title claims abstract description 32
- 206010052428 Wound Diseases 0.000 claims abstract description 60
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 34
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229920001222 biopolymer Polymers 0.000 claims abstract description 34
- 229960002442 glucosamine Drugs 0.000 claims abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 22
- 125000002091 cationic group Chemical group 0.000 claims abstract description 20
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 20
- 238000003825 pressing Methods 0.000 claims abstract description 4
- 159000000021 acetate salts Chemical class 0.000 claims description 27
- 229920001661 Chitosan Polymers 0.000 claims description 26
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 25
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 24
- 229940030225 antihemorrhagics Drugs 0.000 claims description 9
- 239000002874 hemostatic agent Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000012795 verification Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 239000012530 fluid Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 15
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229920006317 cationic polymer Polymers 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002801 charged material Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- -1 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00412—Plasters use for use with needles, tubes or catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
- A61F2013/00472—Plasters use haemostatic with chemical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates to medical devices for hemostasis, and methods of using the medical devices for hemostasis. More particularly, the present invention relates to medical devices for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough.
- Puncture of blood vessels is a necessary stage in many of the minimally invasive approaches to diagnosis and treatment, including interventional radiology and cardiology. Therefore, a need to create hemostasis as rapidly as possible following the procedure becomes an important priority.
- hemostatic agents such as synthetic or natural cationic polymers, hydrogels, collagen based products, oxidized cellulose, gelatin derivatives, topical thrombin, astringents, vasoconstrictors, etc. have been and are being utilized. Most conventional devices and methods of application are designed as a pad or dressing, incorporating these hemostatic agents to the bleeding site, puncture site or wound site.
- Certain medical procedures require insertion of a tubular element, such as catheter, introducer or tube in an artery or other vessel of a patient.
- a tubular element such as catheter, introducer or tube
- the insertion of such tubular element makes it difficult to provide an effective hemostasis at a puncture wound because the hemostatic substances can not be applied quite directly and intimately under pressure to the bleeding or wound site.
- an immediate hemostasis is often needed during surgery while a tubular element is still in the vessels of the patient or after the tubular element is removed. Therefore, what is needed is a simple, safe and effective device and method for providing more directly and intimately hemostasis to the bleeding site with an indwelling tubular element, such as catheter, introducer or tube, and allowing the tubular element to be easily removed thereafter.
- the present invention provides a device and method for effecting hemostasis at a wound site with an indwelling tubular element, such as catheter, introducer or tube disposed therein.
- the cationic substance can be incorporated into many forms, such as woven and non-woven pads, fibers, gels, pastes, waxes, foams, sprays, liquids of varying viscosities, packings, membranes, sheets, and the like. Additionally, these forms can be incorporated and utilized with iontophoretic types of equipment that create a positive charge at the bleeding site to effect coagulation.
- the cationic charge can be provided by a substance with a positively charged surface, or electronically by utilizing electrophoretic type equipment and electrode pads specifically designed to be disposable, conductive and sterile, designed to fit the required anatomical site.
- Many cationic substances are available, such as polymers, polysaccharides and starches, aluminum salts, magnesium salts, natural polymers such as chitosan, and the like.
- ionic charges to create hemostasis is a new and important process in the treatment of disease processes.
- This novel approach can be administered by applying sterile, biocompatible, positively charged materials directly in contact with the blood column, accompanied by pressure, or provided electronically by utilizing controlled direct current on the positive side with iontophoretic type approaches and specially constructed, disposable, sterile electrodes to the bleeding site
- a hemostatic pad defines an opening at an approximately central point of the pad.
- the opening is sized to allow egress of the indwelling tubular element through the pad.
- the pad further comprises an application surface which contains hemostatic agent used for stopping the bleeding at the wound site associated with an indwelling tubular element.
- the hemostatic agent preferably is a cationic substance, such as cationic polymer, or a cationic protein.
- the opening of the pad is a slit extending from an approximate center to an edge of the pad.
- the opening is constructed as an aperture with an elongated cut extending from the aperture to an edge of the pad.
- the slit or the elongated cut is at a bias angle with respect to the central region of the pad.
- the hemostatic pad may have a non-slip etched area on a top surface of the pad, in order to achieve more friction between the finger of a surgeon and the surface of the pad.
- the non-slip etched area make it easier to apply a pressure to a puncture site, and make the hemostasis more efficiently and quickly.
- the present invention also provides a method for effecting hemostasis at a puncture wound with a pad having an opening sized to allow egress of a tubular element disposed in the puncture wound.
- the pad may be applied to or removed from the wound while the tubular element is in the wound.
- the method includes applying pressure proximal to the puncture wound, and directing the application surface, which contains a hemostatically effective amount of cationic substances, of the pad against the puncture wound with sufficient force to prevent fluid from exiting the puncture wound, and permitting the indwelling tubular element going through the pad, removing the pressure on the puncture wound, and maintaining the force on the pad against the wound for a predetermined time period, upon verification (usually visually) of hemostasis, removing the force on the pad.
- the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine.
- the application surface is an acetate salt of a biopolymer of glucosamine.
- the predetermined time period is substantially proportional to the diameter of the tubular element.
- the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer, a catheter or a tube from the puncture wound.
- FIG. 1 is a top view of one embodiment of the present invention showing an opening, particularly a slit extending from an approximately central point to an edge of the pad.
- FIG. 2 is a top view of another embodiment of the present invention showing an opening, particularly an aperture at an approximate center of the pad and a slit extending from the aperture to an edge of the pad.
- FIG. 3 is a top view of a third embodiment of the present invention showing a central non-slip etched area on a top surface of the pad and an opening, particularly a slit extending from a central aperture to an edge of the pad.
- FIG. 4 is a side view of the present invention showing a catheter extending through a disc, wherein the disc having a hemostatic layer attached to a bottom surface of the disc, and an opening permitting egress of the indwelling catheter through the disc.
- FIG. 5 is a side view of an alternative embodiment of the present invention.
- FIG. 5A is a top perspective view of one preferred form of the present invention.
- FIG. 5B is a top perspective view of an alternative form of the present invention.
- the present invention is described hereinafter with specific references to the use of the present invention for sealing an incision or puncture wound with an indwelling tubular element, such as catheter, introducer or tube, through the incision or puncture wound. It is contemplated that the present invention may be used with any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough.
- FIG. 1 is a top view of one preferred embodiment of the present inveniton.
- a pad 10 defines an opening 12 through the pad 10 .
- the opening is constructed as a slit or an elongated cut 26 .
- the slit 26 extends from an approximately central point to an edge of the pad 10 .
- the slit is preferably sized to permit egress of an indwelling tubular element, such as catheter, introducer, or tube (not shown) through the pad 10 .
- the opening 12 is constructed as a generally circular aperture 14 with an elongated cut 26 extending from the aperture 14 to an edge of the pad 10 .
- Other aperture shapes can be sued.
- the pad 10 also contains cationic substances, such as cationic polymer, cationic proteins on a bottom surface (not shown) of the pad.
- FIG. 3 shows another embodiment of the present invention.
- the pad 10 has a generally circular aperture 14 , an elongated cut 26 extending from the aperture 14 to an edge of the pad 10 , and a central non-slip etched area 16 on a top surface of pad 10 in order to provide more friction between the finger of the surgeon and the top surface of the pad.
- the non-slip etched area make it easier to apply a pressure to a puncture site, and make the hemostasis more efficiently and quickly.
- a disc 20 may be used instead of the pad to effect a uniform pressure on the wound site.
- the disc 20 may rigid, semi-rigid, or flexible.
- one embodiment of the present invention comprises a disc 20 and a hemostatic layer 22 attached to a bottom surface of the disc.
- the device also has an opening 12 at an approximately central point of the disc 20 . The opening is sized to permit egress of the indwelling catheter 24 or other medical equipment through the disc.
- FIG. 5 shows an alternative hemostatic device 100 of the present invention.
- the elongated cut 26 is a bias cut at an angle A with respect to the normal to the upper surface of the pad 100 , preferably at 45 degrees, although other angles may be used.
- the opposing bevel surfaces at the cut form a substantial closure across the cut after the flap adjacent to the cut is lifted to permit passage of a catheter (to the aperture) and then lowered again.
- the elongated bias cut extend from the central aperture defined on the pad.
- the pad with the bias cut and the aperture thereof seal the wound around the indwelling tubular element.
- the hemostatic pad only defines an elongated cut or slit extending from an approximately central point of the pad.
- the cut or slit is at a bias angle with respect to the normal of the central region of the pad.
- a surgeon can lift the flap adjacent to the cut to allow passage of an indwelling catheter and then locate the hemostatic pad on the wound with the catheter extending through the central point of the pad. After the catheter is removed, the flap close to the central point is lowered and the bevel surfaces at the cut form a substantial closure across the cut. Thereby, the hemostatic pad seals the wound to prevent the wound from exposure to the air.
- the method for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough includes applying pressure proximal to the puncture wound (not shown) to at least partially collapse the blood vessel (not shown), and directing a cationic application surface of a closure pad 10 against the puncture wound with force sufficient to substantially prevent fluid from exiting the puncture wound, wherein the pad 10 defines an opening 12 therethrough to permit egress of the indwelling tubular element through the pad 10 . Then the pressure proximal to the puncture wound is removed. The method then includes maintaining the force on the closure pad 10 and against the wound for at least a first predetermined time period, and removing the force on the closure pad 10 upon verification of hemostasis. Hemostasis is generally verified visually.
- the first predetermined time period is substantially proportional to a diameter of the tubular element, and thus the resulting puncture wound
- the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used.
- the pressure is not removed from the closure pad 10 and the puncture wound until hemostasis is confirmed. Thus force may need to be maintained on the closure pad 10 for longer than ten minutes.
- a dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad.
- the dressing and the closure pad 10 may be removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed.
- the method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound.
- the hemostatic substance therefore can be applied evenly, directly and intimately around the catheter, introducer or tube, also permitting the even application of pressure for hemostasis. It also allows for easier removal of the indwelling catheter, introducer or tube through the dressing, pad or device.
- the hemostatic pad or device may have a non-slip etched area on the top surface of the pad, in order to provide more friction between the finger of the surgeon and the surface of the pad in order to make the application of pressure to a puncture site more conveniently and allow the puncture site achieve hemostasis more efficiently.
- the hemostatic agent is preferably a cationic biopolymer of glucosamine.
- the cationic biopolymer of glucosamine is provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
- the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part of the biopoly
- the cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization.
- Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates generally to medical devices for applying hemostatic composition to a puncture or wound site with indwelling tubular element, such as catheter, introducer or tube therein, particularly a hemostatic pad with an opening therethrough in order to allow egress of the indwelling tubular element through the hemostatic pad as the hemostatic pad provide hemostasis at the hemorrhaging site. The device may be applied to, or removed from, the wound site while the tubular element is in place. A method for effecting hemostasis at a puncture wound, includes applying pressure proximal to the puncture wound, and directing a cationic biopolymer of glucosamine application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound. Then the pressure proximal to the puncture wound is removed and the force on the closure pad is maintained for at least a first predetermined time period. The force on the closure pad is removed if hemostasis is verified. The puncture wound may then be dressed over the closure pad, and the dressing and the closure pad removed after a second predetermined time period.
Description
- This application is a continuation in part of U.S. patent application Ser. No. 10/008,052, filed Nov. 13, 2001, the disclosure of which is incorporated herein by reference.
- The present invention relates to medical devices for hemostasis, and methods of using the medical devices for hemostasis. More particularly, the present invention relates to medical devices for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough.
- Puncture of blood vessels is a necessary stage in many of the minimally invasive approaches to diagnosis and treatment, including interventional radiology and cardiology. Therefore, a need to create hemostasis as rapidly as possible following the procedure becomes an important priority.
- Various hemostatic agents, such as synthetic or natural cationic polymers, hydrogels, collagen based products, oxidized cellulose, gelatin derivatives, topical thrombin, astringents, vasoconstrictors, etc. have been and are being utilized. Most conventional devices and methods of application are designed as a pad or dressing, incorporating these hemostatic agents to the bleeding site, puncture site or wound site.
- Certain medical procedures require insertion of a tubular element, such as catheter, introducer or tube in an artery or other vessel of a patient. The insertion of such tubular element makes it difficult to provide an effective hemostasis at a puncture wound because the hemostatic substances can not be applied quite directly and intimately under pressure to the bleeding or wound site. However, an immediate hemostasis is often needed during surgery while a tubular element is still in the vessels of the patient or after the tubular element is removed. Therefore, what is needed is a simple, safe and effective device and method for providing more directly and intimately hemostasis to the bleeding site with an indwelling tubular element, such as catheter, introducer or tube, and allowing the tubular element to be easily removed thereafter.
- The present invention provides a device and method for effecting hemostasis at a wound site with an indwelling tubular element, such as catheter, introducer or tube disposed therein.
- Many hemostasis methods have been utilized or attempted, including suture-based devices, collagen plugs, pressure applying devices, and the like. The situation is complicated further by the use of anticoagulants in these procedures, which prolongs clotting times. Substances such as heparin, aspirin, coumadin, and other anticoagulants are used with regularity and affect the normal blood coagulation cascade. The use of cationic substances in flocculation and coagulation in non-medical situations such as water treatment, paper production, industrial sludge treatment, and the like has been effectively used in the past and is well documented. The method of action is by precipitating, coagulating or flocculating suspended particles which are negatively charged by virtue of using positively charged materials, which attract the oppositely charged ions.
- It has been clearly demonstrated that the charge on blood cells and components (platelets, etc.) is negative. By using a positively charged biocompatible substance, it is possible to agglomerate these cells creating coagulation through a system other than by virtue of the normal clotting cascade. Innocuous polymers are positively charged (cationic substances) as the initiator of coagulation in clinical situations. Additionally, positive charges can be applied via iontophoretic methods using electrode pads and positively charged treatment sites to accomplish the same thing.
- The use of a positive charge administered by either cationic substances or by iontophoretic means to quickly create a coagulation process and hemostasis until the normal clotting cascade can take over. This can occur even in the face of significant anticoagulation since the process is ionic and not effected by the anticoagulants, which operate on the normal blood cascade. This approach can be revolutionary in the after treatment of patients with minimally invasive or invasive procedures since rapid hemostasis and mobilization of the patient are desirable endpoints.
- The cationic substance can be incorporated into many forms, such as woven and non-woven pads, fibers, gels, pastes, waxes, foams, sprays, liquids of varying viscosities, packings, membranes, sheets, and the like. Additionally, these forms can be incorporated and utilized with iontophoretic types of equipment that create a positive charge at the bleeding site to effect coagulation.
- Utilizing colloidal chemistry for effecting coagulation ionically in suspensions or colloidal substance by providing cationic charges, has enormous value in the diagnosis and treatment of conditions such as cardiovascular disease, interventional radiological procedures, and the like. The cationic charge can be provided by a substance with a positively charged surface, or electronically by utilizing electrophoretic type equipment and electrode pads specifically designed to be disposable, conductive and sterile, designed to fit the required anatomical site. Many cationic substances are available, such as polymers, polysaccharides and starches, aluminum salts, magnesium salts, natural polymers such as chitosan, and the like.
- The use of ionic charges to create hemostasis is a new and important process in the treatment of disease processes. This novel approach can be administered by applying sterile, biocompatible, positively charged materials directly in contact with the blood column, accompanied by pressure, or provided electronically by utilizing controlled direct current on the positive side with iontophoretic type approaches and specially constructed, disposable, sterile electrodes to the bleeding site
- According to one aspect of the present invention, a hemostatic pad defines an opening at an approximately central point of the pad. The opening is sized to allow egress of the indwelling tubular element through the pad. The pad further comprises an application surface which contains hemostatic agent used for stopping the bleeding at the wound site associated with an indwelling tubular element. The hemostatic agent preferably is a cationic substance, such as cationic polymer, or a cationic protein. The pad, with the indwelling tubular element passing through the opening of the pad, provides an even application of pressure to the wound site. The hemostatic substance on the pad, therefore, may be applied evenly, directly and intimately to the wound site around the tubular element. It also allows the indwelling tubular element to be easily removed from the wound site through the pad. In a preferred embodiment, the opening of the pad is a slit extending from an approximate center to an edge of the pad. In another preferred embodiment, the opening is constructed as an aperture with an elongated cut extending from the aperture to an edge of the pad. In one preferred form, the slit or the elongated cut is at a bias angle with respect to the central region of the pad.
- According to another aspect of the present invention, the hemostatic pad may have a non-slip etched area on a top surface of the pad, in order to achieve more friction between the finger of a surgeon and the surface of the pad. The non-slip etched area make it easier to apply a pressure to a puncture site, and make the hemostasis more efficiently and quickly.
- The present invention also provides a method for effecting hemostasis at a puncture wound with a pad having an opening sized to allow egress of a tubular element disposed in the puncture wound. The pad may be applied to or removed from the wound while the tubular element is in the wound. The method includes applying pressure proximal to the puncture wound, and directing the application surface, which contains a hemostatically effective amount of cationic substances, of the pad against the puncture wound with sufficient force to prevent fluid from exiting the puncture wound, and permitting the indwelling tubular element going through the pad, removing the pressure on the puncture wound, and maintaining the force on the pad against the wound for a predetermined time period, upon verification (usually visually) of hemostasis, removing the force on the pad.
- According to one aspect of the present invention, the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine. In some forms of the invention, the application surface is an acetate salt of a biopolymer of glucosamine.
- According to further aspect of the present invention, when a tubular element is disposed in the wound, the predetermined time period is substantially proportional to the diameter of the tubular element.
- The present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer, a catheter or a tube from the puncture wound. These and other features and benefits of the present disclosure will become more apparent upon reading the following specification in combination with the accompanying drawing figures.
- Other features and advantages of the present invention will be apparent from the following detailed description of the drawing in which:
-
FIG. 1 is a top view of one embodiment of the present invention showing an opening, particularly a slit extending from an approximately central point to an edge of the pad. -
FIG. 2 is a top view of another embodiment of the present invention showing an opening, particularly an aperture at an approximate center of the pad and a slit extending from the aperture to an edge of the pad. -
FIG. 3 is a top view of a third embodiment of the present invention showing a central non-slip etched area on a top surface of the pad and an opening, particularly a slit extending from a central aperture to an edge of the pad. -
FIG. 4 is a side view of the present invention showing a catheter extending through a disc, wherein the disc having a hemostatic layer attached to a bottom surface of the disc, and an opening permitting egress of the indwelling catheter through the disc. -
FIG. 5 is a side view of an alternative embodiment of the present invention; -
FIG. 5A is a top perspective view of one preferred form of the present invention; -
FIG. 5B is a top perspective view of an alternative form of the present invention. - The present invention is described hereinafter with specific references to the use of the present invention for sealing an incision or puncture wound with an indwelling tubular element, such as catheter, introducer or tube, through the incision or puncture wound. It is contemplated that the present invention may be used with any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough.
-
FIG. 1 is a top view of one preferred embodiment of the present inveniton. Referring toFIG. 1 , apad 10 defines anopening 12 through thepad 10. In a preferred embodiment, the opening is constructed as a slit or anelongated cut 26. As shown inFIG. 1 , theslit 26 extends from an approximately central point to an edge of thepad 10. The slit is preferably sized to permit egress of an indwelling tubular element, such as catheter, introducer, or tube (not shown) through thepad 10. In another embodiment of the present invention, as shown inFIG. 2 ., theopening 12 is constructed as a generallycircular aperture 14 with anelongated cut 26 extending from theaperture 14 to an edge of thepad 10. Other aperture shapes can be sued. Thepad 10 also contains cationic substances, such as cationic polymer, cationic proteins on a bottom surface (not shown) of the pad. -
FIG. 3 shows another embodiment of the present invention. Referring toFIG. 3 , thepad 10 has a generallycircular aperture 14, anelongated cut 26 extending from theaperture 14 to an edge of thepad 10, and a central non-slipetched area 16 on a top surface ofpad 10 in order to provide more friction between the finger of the surgeon and the top surface of the pad. The non-slip etched area make it easier to apply a pressure to a puncture site, and make the hemostasis more efficiently and quickly. - A
disc 20 may be used instead of the pad to effect a uniform pressure on the wound site. Thedisc 20 may rigid, semi-rigid, or flexible. As shown inFIG. 4 , one embodiment of the present invention comprises adisc 20 and ahemostatic layer 22 attached to a bottom surface of the disc. The device also has anopening 12 at an approximately central point of thedisc 20. The opening is sized to permit egress of theindwelling catheter 24 or other medical equipment through the disc. -
FIG. 5 shows an alternativehemostatic device 100 of the present invention. As shown inFIG. 5 , the elongated cut 26 is a bias cut at an angle A with respect to the normal to the upper surface of thepad 100, preferably at 45 degrees, although other angles may be used. With that bias cut through thehemostatic pad 100, the opposing bevel surfaces at the cut form a substantial closure across the cut after the flap adjacent to the cut is lifted to permit passage of a catheter (to the aperture) and then lowered again. - In one preferred form, as shown in
FIG. 5A , the elongated bias cut extend from the central aperture defined on the pad. In a medical procedure, when the hemostatic device is applied to a puncture wound with an indwelling tubular element extending therefrom, the pad with the bias cut and the aperture thereof seal the wound around the indwelling tubular element. - In another preferred form, as shown in
FIG. 5B , the hemostatic pad only defines an elongated cut or slit extending from an approximately central point of the pad. The cut or slit is at a bias angle with respect to the normal of the central region of the pad. In a medical procedure, a surgeon can lift the flap adjacent to the cut to allow passage of an indwelling catheter and then locate the hemostatic pad on the wound with the catheter extending through the central point of the pad. After the catheter is removed, the flap close to the central point is lowered and the bevel surfaces at the cut form a substantial closure across the cut. Thereby, the hemostatic pad seals the wound to prevent the wound from exposure to the air. - The method for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough includes applying pressure proximal to the puncture wound (not shown) to at least partially collapse the blood vessel (not shown), and directing a cationic application surface of a
closure pad 10 against the puncture wound with force sufficient to substantially prevent fluid from exiting the puncture wound, wherein thepad 10 defines anopening 12 therethrough to permit egress of the indwelling tubular element through thepad 10. Then the pressure proximal to the puncture wound is removed. The method then includes maintaining the force on theclosure pad 10 and against the wound for at least a first predetermined time period, and removing the force on theclosure pad 10 upon verification of hemostasis. Hemostasis is generally verified visually. - The first predetermined time period is substantially proportional to a diameter of the tubular element, and thus the resulting puncture wound
- In general, however, the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used. In any event, the pressure is not removed from the
closure pad 10 and the puncture wound until hemostasis is confirmed. Thus force may need to be maintained on theclosure pad 10 for longer than ten minutes. A dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad. - After twenty-four hours, the dressing and the
closure pad 10 may be removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed. - The method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound. The hemostatic substance therefore can be applied evenly, directly and intimately around the catheter, introducer or tube, also permitting the even application of pressure for hemostasis. It also allows for easier removal of the indwelling catheter, introducer or tube through the dressing, pad or device. In addition, the hemostatic pad or device may have a non-slip etched area on the top surface of the pad, in order to provide more friction between the finger of the surgeon and the surface of the pad in order to make the application of pressure to a puncture site more conveniently and allow the puncture site achieve hemostasis more efficiently.
- In the above embodiment, the hemostatic agent is preferably a cationic biopolymer of glucosamine. The cationic biopolymer of glucosamine is provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine. In forms including an acetate salt, the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part of the biopolymer of glucosamine.
- In a preferred form, the cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization. Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.
- The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (50)
1. A device for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough, said device comprising:
a pad having a top surface and a bottom surface, said pad defining an aperture near a central region thereof adapted for passage therethrough of said tubular element, and an elongated cut extending from said aperture to a peripheral point of said pad; and
a hemostatically effective amount of a hemostatic agent on said bottom surface of said pad.
2. The device of claim 1 , wherein the hemostatic agent comprises a cationic biopolymer of glucosamine,
3. The device of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
4. The device of claim 2 , wherein the biopolymer of glucosamine is poly-D-glucosamine.
5. The device of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
6. The device of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
7. The device of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
8. The device of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
9. The device of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
10. The device of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
11. The device of claim 1 , wherein the tubular element is a catheter.
12. The device of claim 1 , wherein the tubular element is an introducer.
13. The device of claim 1 , wherein the tubular element is a tube.
14. The device of claim 1 , wherein said aperture is at an approximate center of said pad.
15. The device of claim 1 , wherein said aperture and said cut form a slit.
16. The device of claim 15 , wherein said slit is at a bias angle with respect to the central region of the pad.
17. The device of claim 16 , wherein said slit is at a bias angle of 45 degrees with respect to the central region of the pad.
18. The device of claim 1 further comprising a central non-slip etched area on a top surface of said pad.
19. The device of claim 1 , wherein said cut is at a bias angle with respect to the central region of the pad.
20. The device of claim 19 , wherein said cut is at a bias angle of 45 degrees with respect to the central region of the pad.
21. A device for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough, said device comprising:
a disc having a hemostatic layer attached to a bottom surface of said disc, wherein said disc defines an aperture through said disc, and wherein said aperture is adapted to permit egress of the indwelling tubular element through said disc, and wherein said disc defines a cut extending from said aperture to a peripheral point of said disc.
22. The device of claim 21 , wherein the hemostatic layer comprises a cationic biopolymer of glucosamine,
23. The device of claim 22 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
24. The device of claim 22 , wherein the biopolymer of glucosamine is poly-D-glucosamine.
25. The device of claim 22 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
26. The device of claim 22 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
27. The device of claim 22 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
28. The device of claim 22 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
29. The device of claim 22 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
30. The device of claim 22 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
31. The device of claim 21 , wherein the tubular element is a catheter.
32. The device of claim 21 , wherein the tubular element is an introducer.
33. The device of claim 21 , wherein the tubular element is a tube.
34. The device of claim 21 , wherein said aperture and said cut form a slit extending from an approximately central point to an edge of said disc.
35. The device of claim 34 , wherein said slit is at a bias angle with respect to a central region of the disc.
36. The device of claim 35 , wherein said slit is at a bias angle of 45 degrees with respect to the central region of the disc.
37. The device of claim 21 further comprising a central non-slip etched area on a top surface of said disc.
38. The device of claim 21 , wherein said cut is at a bias angle with respect to a central region of the disc.
39. The device of claim 38 , wherein said cut is at a bias angle of 45 degrees with respect to the central region of the pad.
40. A method for effecting hemostasis at a puncture wound with an indwelling tubular element extending therethrough, said method comprising:
A) applying pressure proximal to the puncture wound in order to at least partially prevent blood from exiting the puncture wound;
B) providing a closure pad having an application surface bearing a hemostatically effective amount of a hemostatic agent thereon, and wherein said pad defines an aperture therethough to permit egress of said indwelling tubular element through said pad, and includes a cut extending from said aperture to a peripheral point of said pad;
C) directing said pad toward the wound while guiding said cut about said tubular element until said tubular element is resident in said aperture and said application surface is disposed about and to the wound;
D) directing force against said pad sufficient to substantially prevent blood from exiting the puncture wound;
E) removing the pressure proximal to the puncture wound;
F) maintaining the force on said closure pad against the puncture wound for at least a first predetermined time period; and
G) removing the force on said closure pad upon verification of hemostasis.
41. The method of claim 40 further comprising the step of:
removing said pad while said tubular element remains in place.
42. The method of claim 40 , wherein the hemostatic agent comprises a cationic biopolymer of glucosamine,
43. The method of claim 42 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
44. The method of claim 42 , wherein the biopolymer of glucosamine is poly-D-glucosamine.
45. The method of claim 42 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
46. The method of claim 42 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
47. The method of claim 42 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
48. The method of claim 42 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
49. The method of claim 42 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
50. The method of claim 42 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/125,765 US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/008,052 US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
US10/286,566 US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US11/125,765 US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/286,566 Division US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050222615A1 true US20050222615A1 (en) | 2005-10-06 |
Family
ID=21729584
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/008,052 Pending US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
US10/267,902 Abandoned US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/267,940 Abandoned US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/286,614 Expired - Lifetime US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,566 Expired - Lifetime US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US11/125,765 Abandoned US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/008,052 Pending US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
US10/267,902 Abandoned US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/267,940 Abandoned US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/286,614 Expired - Lifetime US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,566 Expired - Lifetime US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
Country Status (3)
Country | Link |
---|---|
US (6) | US20030093114A1 (en) |
AU (1) | AU2002363798A1 (en) |
WO (1) | WO2003041564A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110112572A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
US20110108199A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
US8302323B2 (en) | 2010-06-21 | 2012-11-06 | Confluent Surgical, Inc. | Hemostatic patch |
US8961479B2 (en) * | 2013-03-19 | 2015-02-24 | Biolife, L.L.C. | Hemostatic device and method |
WO2021134005A1 (en) * | 2019-12-27 | 2021-07-01 | Hg Medical Technologies Llc | Iontophoretic wound treatment device |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003065877A2 (en) * | 2002-02-04 | 2003-08-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
AU2003294238A1 (en) * | 2002-10-30 | 2004-06-07 | Joel S. Rossen | Simplified one-handed preemptive medical procedure site dressing to prevent sharps injuries and exposure to bloodborne pathogens |
US7943810B2 (en) | 2003-02-04 | 2011-05-17 | Buckman Robert F | Method and apparatus for hemostasis |
US7955616B2 (en) * | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
EP1677664B1 (en) * | 2003-09-23 | 2014-07-30 | Orthocon Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
US20050267520A1 (en) | 2004-05-12 | 2005-12-01 | Modesitt D B | Access and closure device and method |
US7678133B2 (en) | 2004-07-10 | 2010-03-16 | Arstasis, Inc. | Biological tissue closure device and method |
US20060276838A1 (en) * | 2005-06-07 | 2006-12-07 | Wensel Jeffrey P | Vascular puncture sealing method, apparatus, and system |
US7622628B2 (en) * | 2005-05-04 | 2009-11-24 | Innovasa Corporation | Hemostatic wire guided bandage and method of use |
US20060276836A1 (en) * | 2005-06-07 | 2006-12-07 | Bergin Patrick J | Hemostatic wire guided bandage and method of use |
US20080015481A1 (en) * | 2005-05-04 | 2008-01-17 | Bergin Patrick J | Hemostatic bandage and method of use |
CN103190942A (en) | 2005-05-12 | 2013-07-10 | 阿尔斯塔西斯公司 | Access and closure device and method |
US20080269659A1 (en) * | 2005-06-07 | 2008-10-30 | Bergin Patrick J | Hemostatic Bandage |
US20070122361A1 (en) * | 2005-11-29 | 2007-05-31 | Weitao Jia | Tooth colorant and whitener, method of manufacture, and method of use thereof |
US20070154509A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US20070154510A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
US7645252B2 (en) | 2006-05-16 | 2010-01-12 | Barbara Brooke Jennings-Spring | Body or plant part dressing |
US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
US20090287133A1 (en) * | 2006-06-06 | 2009-11-19 | Lagreca Sr Alfred J | Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System |
US20080097270A1 (en) * | 2006-08-25 | 2008-04-24 | Utterberg David S | Resilient hemostasis devices |
US20080063697A1 (en) * | 2006-09-08 | 2008-03-13 | Bedard Robert L | Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products |
US8623842B2 (en) * | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
US8100937B2 (en) | 2006-10-10 | 2012-01-24 | Smalling Medical Ventures, Llc | Pressure assist system for facilitating vascular hemostasis, and associated method |
US7931651B2 (en) * | 2006-11-17 | 2011-04-26 | Wake Lake University Health Sciences | External fixation assembly and method of use |
US20080145455A1 (en) * | 2006-12-13 | 2008-06-19 | Bedard Robert L | Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents |
US9066885B2 (en) * | 2007-03-16 | 2015-06-30 | University Of Maryland, College Park | Advanced functional biocompatible polymeric matrix containing nano-compartments |
US8932560B2 (en) * | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
US8597253B2 (en) | 2007-04-20 | 2013-12-03 | Bard Access Systems | Huber needle with safety sheath |
US20090047366A1 (en) * | 2007-08-15 | 2009-02-19 | Bedard Robert L | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants |
US8883194B2 (en) * | 2007-11-09 | 2014-11-11 | Honeywell International, Inc. | Adsorbent-containing hemostatic devices |
US8795718B2 (en) * | 2008-05-22 | 2014-08-05 | Honeywell International, Inc. | Functional nano-layered hemostatic material/device |
CA2730362C (en) | 2008-07-18 | 2018-07-10 | Wake Forest University Health Sciences | Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage |
AU2009274127A1 (en) | 2008-07-21 | 2010-01-28 | Arstasis, Inc. | Devices, methods, and kits for forming tracts in tissue |
US8668899B2 (en) | 2009-11-13 | 2014-03-11 | University Of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
CN101862469B (en) * | 2010-05-28 | 2013-03-13 | 武汉人福医疗用品有限公司 | Chitosan derivative quick hemostasis granules and preparation method thereof |
US20130110025A1 (en) * | 2010-07-14 | 2013-05-02 | Hemcon Medical Technologies (Ip) Limited | Dressing device for use wtih a cannula or a catheter |
EP2603246B1 (en) | 2010-08-13 | 2019-04-03 | University of Maryland, College Park | Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes |
US10525234B2 (en) | 2010-09-10 | 2020-01-07 | C. R. Bard, Inc. | Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin |
US20140066894A1 (en) | 2010-09-10 | 2014-03-06 | C. R. Bard, Inc. | Self-Sealing Pad for a Needle-Based Infusion Set |
US9248234B2 (en) | 2010-09-10 | 2016-02-02 | C. R. Bard, Inc. | Systems for isolation of a needle-based infusion set |
US9427360B2 (en) | 2010-11-04 | 2016-08-30 | W. Jerry Mezger | Hemostatic fabric |
WO2012075457A2 (en) | 2010-12-02 | 2012-06-07 | University Of Maryland, College Park | Method and system for capture and use of intact vesicles on electrodeposited hydrophobically modified biopolymer films |
US9561300B2 (en) | 2011-09-26 | 2017-02-07 | Yes, Inc. | Hemostatic compositions and dressings for bleeding |
US20130317481A1 (en) | 2012-05-25 | 2013-11-28 | Arstasis, Inc. | Vascular access configuration |
US20130317438A1 (en) | 2012-05-25 | 2013-11-28 | Arstasis, Inc. | Vascular access configuration |
US8658193B2 (en) * | 2012-06-08 | 2014-02-25 | Robert J. Greenwald | Styptic storage and delivery |
US8889655B2 (en) | 2012-07-20 | 2014-11-18 | Aegis Women's Health Technologies | Compositions and methods for preventing infectious diseases in females |
US8969649B2 (en) * | 2012-08-10 | 2015-03-03 | Ethicon, Inc. | Integrated dressing device |
WO2014137824A1 (en) * | 2013-03-07 | 2014-09-12 | Life Sciences Llc | Apparatus & method for wound infection prevention |
WO2014160136A1 (en) | 2013-03-13 | 2014-10-02 | University Of Maryland, Office Of Technology Commercialization | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
US20150057640A1 (en) * | 2013-08-22 | 2015-02-26 | Evelyn M. Tarkington | Circular bandage for drain tube |
US10195399B2 (en) | 2013-10-29 | 2019-02-05 | Avent, Inc. | Catheter securement device |
US9764116B2 (en) | 2013-12-30 | 2017-09-19 | Avent, Inc. | Catheter insertion site plug |
US10556093B2 (en) | 2013-12-31 | 2020-02-11 | Confluence, LLC | Medical devices, dressings, and methods for closing openings in tissue |
US10406255B2 (en) | 2014-05-28 | 2019-09-10 | Highland Industries, Inc. | Hemostatic textile |
US11627795B2 (en) | 2017-02-14 | 2023-04-18 | G-Tech Llc | Shoulder transfer weight support system and face shield |
WO2019221201A1 (en) * | 2018-05-16 | 2019-11-21 | テルモ株式会社 | Compression device and compression method |
CN110538024B (en) * | 2019-09-03 | 2022-06-14 | 重庆市渝北区人民医院 | Portable medical pressurizing application device, use method and application |
US11272941B1 (en) | 2020-08-07 | 2022-03-15 | William P Buchanan | Secondary device holder and compression system, method of making and using the same |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632754A (en) * | 1968-02-12 | 1972-01-04 | Lescarden Ltd | Use of chitin for promoting wound healing |
IT1027501B (en) * | 1968-12-06 | 1978-12-20 | Muzzarelli Weckx M G F | CHITIN CHITOSAN AND DERIVATIVES USED AS CHROMATOGRAPHIC SUPPORTS AND AS ADSORBENTS FOR THE COLLECTION OF IONS FROM WATER AND ORGANIC SOLUTIONS FROM DRINKING AND SEA WATER |
US3969189A (en) * | 1971-12-14 | 1976-07-13 | Kumiai Chemical Industry Co., Ltd. | Cell wall-lysing complex enzymes and a process for the production thereof |
US3811438A (en) | 1972-03-30 | 1974-05-21 | G Economou | Adhesive tapes and bandages |
US4059097A (en) * | 1976-11-03 | 1977-11-22 | American Cyanamid Company | Method of minimizing tissue reaction during surgery with chitin |
US4394373A (en) * | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
US4532134A (en) * | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
US5203764A (en) * | 1985-10-04 | 1993-04-20 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US4833238A (en) * | 1986-12-16 | 1989-05-23 | E. I. Du Pont De Nemours And Company | High strength fibers from chitin derivatives |
FR2616318A1 (en) * | 1987-06-15 | 1988-12-16 | Centre Nat Rech Scient | ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME |
US4784653A (en) * | 1987-06-22 | 1988-11-15 | Johnson & Johnson Patient Care, Inc. | Absorbent adhesive dressing |
US5086764A (en) * | 1989-04-13 | 1992-02-11 | Thomas Gilman | Absorbent dressing |
US4981133A (en) * | 1989-10-10 | 1991-01-01 | Rollband Ernest J | Pressure bandage for puncture wounds with a target marketing |
US5310402A (en) * | 1990-12-03 | 1994-05-10 | Rollband Ernest J | Temporary bandage tape |
US5324252A (en) * | 1991-03-25 | 1994-06-28 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US5429591A (en) * | 1991-07-22 | 1995-07-04 | Nitto Denko Corporation | Absorbent dressing having backing and continuous adhesive layer |
US5269803A (en) * | 1992-04-10 | 1993-12-14 | Gtr Patent, Inc. | Hemostasis pressure pad band |
US5375588A (en) * | 1992-08-17 | 1994-12-27 | Yoon; Inbae | Method and apparatus for use in endoscopic procedures |
US5336219A (en) * | 1993-03-23 | 1994-08-09 | Medi-Flex Hospital Products, Inc. | Skin closure system |
US5683354A (en) * | 1993-07-06 | 1997-11-04 | Levy; Raymond H. | Adhesive bandage for a digit of a human hand or foot |
US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5653730A (en) * | 1993-09-28 | 1997-08-05 | Hemodynamics, Inc. | Surface opening adhesive sealer |
US5714543A (en) * | 1994-01-13 | 1998-02-03 | Bristol-Myers Squibb Company | Water soluble polymer additives for polyurethane-based pressure sensitive adhesives |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5533962A (en) * | 1995-05-12 | 1996-07-09 | Peterman; Shadi | Ringless adhesive bandage |
US5795317A (en) * | 1995-06-07 | 1998-08-18 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods and apparatus |
US5836970A (en) | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
US5807341A (en) * | 1996-12-11 | 1998-09-15 | Team Medical Llc | Medical catheter dressing device |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
US6478808B2 (en) * | 1997-12-17 | 2002-11-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
ES2269069T3 (en) | 1999-06-08 | 2007-04-01 | Ethicon, Inc. | WOVEN SURGICAL MESH. |
US6984219B2 (en) * | 1999-09-23 | 2006-01-10 | Mark Ashby | Depth and puncture control for blood vessel hemostasis system |
US6586651B2 (en) * | 1999-11-01 | 2003-07-01 | John Patrick Sullivan | Adhensive bandage with soft, three-dimensional toy |
US7012169B2 (en) * | 2000-04-06 | 2006-03-14 | Kimberly-Clark Worldwide, Inc. | Disposable finger sleeve for appendages |
US6316686B1 (en) * | 2000-06-20 | 2001-11-13 | Timothy N. Byrd | Medical pressure dressing and process |
-
2001
- 2001-11-13 US US10/008,052 patent/US20030093114A1/en active Pending
-
2002
- 2002-10-09 US US10/267,902 patent/US20030148994A1/en not_active Abandoned
- 2002-10-09 US US10/267,940 patent/US20030153528A1/en not_active Abandoned
- 2002-11-01 US US10/286,614 patent/US6638296B2/en not_active Expired - Lifetime
- 2002-11-01 US US10/286,566 patent/US6890344B2/en not_active Expired - Lifetime
- 2002-11-13 WO PCT/US2002/036564 patent/WO2003041564A2/en not_active Application Discontinuation
- 2002-11-13 AU AU2002363798A patent/AU2002363798A1/en not_active Abandoned
-
2005
- 2005-05-10 US US11/125,765 patent/US20050222615A1/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110112572A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
US20110108199A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
US8302323B2 (en) | 2010-06-21 | 2012-11-06 | Confluent Surgical, Inc. | Hemostatic patch |
US8468708B2 (en) | 2010-06-21 | 2013-06-25 | Confluent Surgical, Inc. | Hemostatic patch |
US8961479B2 (en) * | 2013-03-19 | 2015-02-24 | Biolife, L.L.C. | Hemostatic device and method |
US9877728B2 (en) | 2013-03-19 | 2018-01-30 | Biolife, L.L.C. | Hemostatic device and method |
WO2021134005A1 (en) * | 2019-12-27 | 2021-07-01 | Hg Medical Technologies Llc | Iontophoretic wound treatment device |
Also Published As
Publication number | Publication date |
---|---|
WO2003041564A2 (en) | 2003-05-22 |
US20030093075A1 (en) | 2003-05-15 |
US6890344B2 (en) | 2005-05-10 |
US20030093114A1 (en) | 2003-05-15 |
US20030148994A1 (en) | 2003-08-07 |
WO2003041564A3 (en) | 2003-12-04 |
AU2002363798A1 (en) | 2003-05-26 |
US6638296B2 (en) | 2003-10-28 |
US20030153528A1 (en) | 2003-08-14 |
US20030093115A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6890344B2 (en) | Hemostasis pad and method | |
WO2004041313A2 (en) | Hemostasis pad and method | |
US9320653B2 (en) | Hemostatic compositions and uses therefor | |
JP5127941B2 (en) | Vascular wound closure device | |
CA2737446C (en) | Wound care device | |
CA2184443C (en) | Self-adhesive hydrogel wound dressing | |
EP2233157A1 (en) | A biocompatible denatured starch sponge material | |
JP2005511237A (en) | Apparatus and method for performing coagulant treatment with external pressure on stab wound | |
EP3500221B1 (en) | Collagen/orc dressing encapsulated within a bioresorbable envelope | |
JP6144683B2 (en) | Closure device for closing open blood vessels | |
Kumar et al. | Hemostasis and post-operative care of oral surgical wounds by Hemcon dental dressing in patients on oral anticoagulant therapy: a split mouth randomized controlled clinical trial | |
US8900263B2 (en) | Slotted introducer needle and method for accessing a body lumen | |
EP2934348B1 (en) | Vessel closure system | |
Ingraham et al. | Studies on fibrin foam as a hemostatic agent in neurosurgery, with special reference to its comparison with muscle | |
Gwynne et al. | An overview of the common methods of wound debridement | |
Balzer et al. | Postinterventional percutaneous closure of femoral artery access sites using the Clo-Sur PAD device: initial findings | |
Butcher | A systematic approach to complex wounds | |
US20150342787A1 (en) | Invasive medical device dressing and method of application | |
RU1789211C (en) | Composition for microtraumas treatment | |
JP2015505680A (en) | Neurosurgical sponge device with dissolved layer | |
Eason et al. | The effect of Celox™ Vascular in a Vascular Access Model | |
EP2442830A2 (en) | Hemostatic material and delivery device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |